Analysis – Page 406 – Goldea Capital

Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program

Written by Customer Service on May 7, 2026. Posted in Public Companies.

Company announcement No. 13 / 2026 Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back programRobust cash position of USD 2.3 billion (DKK 14.5 billion) as of March 31, 2026 Financial strength to be further enhanced by significant milestone payments of USD 700 million from Roche in 2026 Continuing to invest significantly in research capabilities to build a leading metabolic health pipeline and execute on Metabolic Frontier 2030 strategyCopenhagen, Denmark, May 7, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces that it has decided to initiate a share buy-back program (the “Program”), under which the Company will buy back own shares for a maximum total consideration of...

Sanoma Corporation, Interim Report 1 January–31 March 2026: Improved adjusted operating profit in Learning and Media

Written by Customer Service on May 7, 2026. Posted in Earnings Releases And Operating Results.

Sanoma Corporation, Stock Exchange Release, 7 May 2026 at 7:30 a.m. EET Sanoma Corporation, Interim Report 1 January–31 March 2026: Improved adjusted operating profit in Learning and Media This release is a summary of Sanoma’s Interim Report 1 January–31 March 2026. The complete report is attached to this release and is also available at www.sanoma.com/en/investors. Q1 2026Net sales were stable and amounted to EUR 221.1 million (2025: 221.1). In Learning, net sales grew, driven by the Netherlands, Spain and Poland. Net sales declined in Media Finland due to lower advertising sales. The Group’s organic net sales development was 0% (2025: 0%). Adjusted operating profit improved to EUR -16.1 million (2025: -18.8) while being negative in line with the typical seasonality of the learning business. In Learning, earnings were supported by higher...

onsemi Announces Pricing of Private Offering of $1.3 Billion of 0% Convertible Senior Notes

Written by Customer Service on May 7, 2026. Posted in Public Companies.

SCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) — ON Semiconductor Corporation (Nasdaq: ON) (“onsemi”) announced today the pricing of its private offering of $1.3 billion aggregate principal amount of 0% Convertible Senior Notes due 2031 (the “notes”) at an approximately 52.5% premium to the closing price of onsemi’s common stock on May 6, 2026 of $105.77 per share. The notes were offered only to persons reasonably believed to be qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). onsemi has granted to the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $200.0 million aggregate principal amount of the notes. The offering of the notes...

Suja Life Announces Pricing of Initial Public Offering

Written by Customer Service on May 7, 2026. Posted in Public Companies.

OCEANSIDE, Calif., May 07, 2026 (GLOBE NEWSWIRE) — Suja Life, Inc. today announced the pricing of its initial public offering of 8,888,889 shares of its Class A common stock (“Class A Common Stock”) which are being offered by Suja Life as described in the registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (the “SEC”), at a public offering price of $21.00 per share. Suja Life has granted the underwriters a 30-day option to purchase up to an additional 1,333,333 shares of Class A Common Stock at the initial public offering price, less the underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market on May 7, 2026 under the ticker symbol “SUJA.” The offering is expected to close on May 8, 2026 subject to customary closing conditions. Upon...

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

Written by Customer Service on May 7, 2026. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its common stock at a price to the public of $71.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, are expected to be approximately $700 million. The offering is expected to close on May 8, 2026, subject to customary closing conditions. Additionally, Cytokinetics has granted the underwriters a 30-day option to purchase up to an additional 1,478,873 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common...

InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China

Written by Customer Service on May 7, 2026. Posted in Public Companies.

BEIJING, May 06, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to initiate a clinical trial of its novel CDH17 targeted ADC, ICP-B208. CDH17 is a calcium-dependent cell adhesion protein that plays a key role in tumor cell proliferation, migration, and metastasis. Its tumor-restricted expression and functional role in cancer biology make CDH17 an attractive and differentiated target for ADC therapy, which can be developed for the treatment of gastrointestinal cancers, including colorectal, gastric, pancreatic ductal adenocarcinoma, and biliary...

McEwen Generates Strong Q1 Results & Advances Multi-Asset Growth Strategy; Net Income $33.4M ($0.56 per Share) vs. Net Loss $6.3M ($0.12 per Share) in Q1 2025; Internally Funding Key Projects to Double Production by 2030

Written by Customer Service on May 7, 2026. Posted in Earnings Releases And Operating Results.

TORONTO, May 06, 2026 (GLOBE NEWSWIRE) — McEwen Inc. (NYSE/TSX: MUX) (“McEwen” or the “Company”) today announced its first quarter financial results for the period ended March 31, 2026 (Q1), along with an update on its development projects, including an updated Mineral Resource Estimate and strong exploration results across all sites as the Company is advancing its plan to increase production to 250,000 – 300,000 GEOs by 2030. Based on current gold and silver prices, McEwen believes that if mine operations meet guidance, the Company can self-fund its future production growth with limited share dilution. This will be a key driver behind growing our share price. Strong Gold Prices Continue to Support Advancement of Key Projects: Canada In Canada, McEwen is advancing growth projects to increase production from 16,000 – 19,000 GEOs...

Fortuna Reports Results for the First Quarter 2026

Written by Customer Service on May 7, 2026. Posted in Earnings Releases And Operating Results.

(All amounts are expressed in US dollars, tabular amounts in millions, unless otherwise stated)Fortuna generates record quarterly free cash flow1 of $174.0 million and adjusted attributable net income1 of $111.0 million VANCOUVER, British Columbia, May 06, 2026 (GLOBE NEWSWIRE) — Fortuna Mining Corp. (NYSE: FSM | TSX: FVI) (“Fortuna” or the “Company”) today reported its financial and operating results for the first quarter of 2026.(Results from the Company’s San Jose and Yaramoko assets have been excluded from the 2025 comparative figures, due to the classification of the assets as discontinued in the previous period.) “Fortuna delivered new quarterly record results with free cash flow of $174.0 million and adjusted attributable earnings of $111.0 million while producing 72,872 gold equivalent ounces which keeps us on track...

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Written by Customer Service on May 7, 2026. Posted in Public Companies.

JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (Nasdaq: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that on April 30, 2026, the Compensation Committee of the Company’s Board of Directors approved inducement equity awards for a new Vice President in connection with the commencement of employment with the Company. The awards were granted as a material inducement to the employee’s acceptance of employment and were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The awards were granted pursuant to SCYNEXIS’ 2015 Inducement Award Plan, as amended, which was adopted by the Company’s Board of Directors in March 2015 under...

Enerflex Ltd. Announces Election of Directors

Written by Customer Service on May 7, 2026. Posted in Public Companies.

CALGARY, Alberta, May 06, 2026 (GLOBE NEWSWIRE) — Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) (“Enerflex” or the “Company”), announces that at its Annual and Special Meeting of Shareholders (the “Meeting”) held virtually on May 6, 2026, Enerflex’s shareholders approved the election of all 10 nominee directors presented in the Company’s Management Information Circular dated March 20, 2026. The shares represented at the Meeting voting on individual nominee directors were as follows: Approval AgainstDirector Votes For Percentage Votes Against PercentageFernando R. Assing 86,602,468 97.65% 2,088,077 2.35%Benjamin Cherniavsky 86,622,946 97.67% 2,067,599 2.33%Joanne Cox 86,155,032 97.14% 2,535,513 2.86%Céline B. Gerson 86,706,678 97.76% 1,983,867 2.24%James C. Gouin 88,278,871 99.54% 411,674 0.46%Mona...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals